

This publication was withdrawn on 22 March 2023. Read the [UK government's current action plan for antimicrobial resistance](#).



World Health
Organization
REGIONAL OFFICE FOR
Europe



Всемирная организация
здравоохранения
Европейское региональное бюро



Organisation
mondiale de la Santé
BUREAU RÉGIONAL DE L'
Europe



Weltgesundheitsorganisation
REGIONALBÜRO FÜR
Europa

European strategic action plan on antibiotic resistance 2011–2016


Dr Guenael Rodier
Director, Division of Communicable Diseases, Health Security
and Environment




Background

- Antimicrobial resistance (AMR) not a new phenomenon, but **increasing** and new resistant strains continue to emerge
- **Misuse of antibiotics** (health, agriculture) and poor infection control responsible for AMR emergence and spread; important link between use of antibiotics in agriculture and resistance to human strains
- Very few new antibiotics in the pipeline
- **World Health Day 2011**: committing to fight AMR

Regional focus on AMR related to bacterial infections, particularly in health care settings, and multidrug-/extensively drug-resistant tuberculosis (M/XDR-TB)




Global burden of AMR



TB

- 440 000 new MDR-TB cases annually
- XDR-TB reported in 58 countries




Malaria (*Plasmodium falciparum*)

- Artemisinin resistance linked to monotherapy


HIV

- With expanded use of antiretrovirals, resistance now a concern




Health-care-associated infections

- Lethal methicillin-resistant *Staphylococcus aureus* (MRSA) is a significant threat in hospitals
- *Escherichia coli* and *Klebsiella pneumoniae* resistant to multiple drugs on the rise
- Increasing resistance in gonorrhoea and shigellosis



Justification


- AMR costs money, livelihoods and lives, and undermines health programmes
- **World Health Assembly resolutions** in 1984, 1998, 2001, 2005
- **WHO global strategy for containment of AMR** published in 2001
- AMR action plans for European Union (EU) Member States
- Member States in transition still require guidance
- **Coherent and concrete strategy needed for the WHO European Region**



AMR in the European Region

- AMR as high as 25% in some Member States
- Every year, 25 000 people die of resistant infections in hospitals in the EU (+ Norway and Iceland)
- About €1.5 billion in extra hospital, treatment, societal costs
- Lack of systematic approach for all sectors
- Poor health systems and weak regulation in many countries
- Insufficient commitment and action plans
- Low awareness among the public and health care professionals

Proportion of MRSA isolates in western Europe, 2008



Source: European Centre for Disease Prevention and Control

European strategic action plan on antibiotic resistance

- Reduce morbidity, mortality and related costs
- Raise awareness of the emergence and spread of antibiotic resistance
- Promote national coordination and action plans
- Promote prudent use of antibiotics and infection control
- Address antibiotic use in human and animals
- Promote innovative financing to develop new antibiotics
- Promote involvement of patient safety groups

Strategic objectives

1. Strengthen intersectoral coordination

- Comprehensive national action plans
- Multisectoral and interdisciplinary national coordination mechanisms

2. Strengthen surveillance of antibiotic resistance

- National surveillance systems, collecting, analysing and reporting data to monitor trends
- Regional databases, tools and standards

3. Promote rational use of antibiotics and strengthen surveillance

- National mechanisms for coordination
- National guidelines on prudent use of antibiotics
- Surveillance of antibiotic consumption

4. Strengthen infection control and surveillance in health care settings

- Prevention of hospital-acquired infections
- Hospital infection control and surveillance committees

Strategic objectives

5. Prevent emerging resistance in veterinary and food sectors

- Prudent use of antibiotics in these sectors
- Integrated systems for surveillance of antibiotic resistance and use

6. Promote innovation and research on new drugs

- International surveillance networks and information sharing on promising research areas
- Active role in research for governments and academic networks; national and international task forces

7. Improve awareness, patient safety, and partnership

- Educational initiatives, behaviour change campaigns and awareness programmes for health care providers and the public
- Broad partnership at national, regional and global levels

Considerations for implementation and monitoring

- Strategic action plan with:
 - time frame for implementation
 - estimated resource needs
 - input, process and output indicators to monitor progress
- Stepwise approach:
 - mapping of available data,
 - identification of current practices
- Support to Member States in:
 - developing and implementing national action plans
 - establishing national coordinating mechanisms

Timeline, 2010–2012

- Expert consultation, 25 August 2010
- European Antibiotic Awareness Day, 18 November 2010, with the European Centre for Disease prevention and Control (ECDC)
- World Health Day 2011, 7 April 2011
- **WHO regional strategy and resolution presented to the sixty-first session of the WHO Regional Committee for Europe, September 2011**
- Publication of regional action plan, 2011
- Country assessment missions, 2011–2012
- Expansion of EU surveillance protocols to Member States outside the EU, 2011–2012

Partners

- **ECDC**
- **CDC** (Centers for Disease Control and Prevention, United States of America)
- **Gates Foundation, CGD** (Center for Global Development)
- **TATFAR** (Trans Atlantic Task Force on Antimicrobial Resistance)
- **ReACT** (Action on Antibiotic Resistance)
- **APUA** (Alliance for the Prudent Use of Antibiotics)
- **IFPMA** (International Federation of Pharmaceutical Manufacturers and Associations)
- **FIP** (International Pharmaceutical Federation)
- **UNITAID, the Global Fund, Stop TB Partnership, Roll Back Malaria, UNAIDS** (Joint United Nations Programme on HIV/AIDS)
- **WHONET** (information system for monitoring antimicrobial resistance, Brigham and Women's Hospital, Boston, United States)
- **Governments** (e.g. the Netherlands, Sweden)

Draft resolution

Member States

- Ensure political commitment and resources for developing and implementing national plans
- Strengthen surveillance and monitoring of antibiotic resistance and consumption
- Establish multisectoral and comprehensive coordination and cooperation mechanisms
- Adhere to infection control
- Raise awareness through national campaigns

WHO Regional Office for Europe

- Provide strategic leadership, guidance and tools for implementing the strategic action plan
- Support Member States in implementing national plans
- Create platforms for sharing and analysing data and experience
- Engage in broad regional and global partnerships
- Promote innovation and research



World Health
Organization

REGIONAL OFFICE FOR
Europe



Всемирная организация
здравоохранения

Европейское региональное бюро



Organisation
mondiale de la Santé

BUREAU RÉGIONAL DE L'
Europe



Weltgesundheitsorganisation

REGIONALBÜRO FÜR
Europa

Thank you

WHO REGIONAL COMMITTEE FOR EUROPE – 61ST SESSION

Baku, Azerbaijan, 12–15 September 2011

COMITÉ RÉGIONAL DE L'OMS POUR L'EUROPE – 61^E SESSION

Bakou (Azerbaïdjan), 12-15 septembre 2011

WHO-REGIONALKOMITEE FÜR EUROPA – 61. TAGUNG

Baku (Aserbaidschan), 12.–15. September 2011

ЕВРОПЕЙСКИЙ РЕГИОНАЛЬНЫЙ КОМИТЕТ ВОЗ – 61-я СЕССИЯ

Баку, Азербайджан, 12–15 сентября 2011 г.

